Meta-analysis Of The Efficacy Of Bevacizumab In Adjuvant Treatment Of Brain Metastases From Lung Cancer

Objective: A systematic review of the effect of bevacizumab on the prognosis of lung cancer patients with brain metastasesMethods: The databases of CNKI,Wanfang,Pub Med,EMBASE and Cochrane were searched,and all the relevant literature on bevacizumab in the treatment of lung cancer brain metastasis from the establishment of each database to March 2022 was collected.Two researchers independently screened the literature according to the inclusion and exclusion criteria.Then,the quality of the selected documents was evaluated,and the materials and data related to the research purpose were extracted from the qualified documents,using revman5.4 software for metaanalysis.Results: 10 of 179 literatures were selected for inclusion in the study.After analysis,it was found that the objective remission rate of the experimental group（treated with bevacizumab）（or = 2.14,95% CI: 1.68-2.74,P < 0.05）,1-year PFS（or = 2.22,95% CI: 1.41-3.50,P < 0.05）,1-year OS（or = 2.09,95% CI: 1.54-2.84,P < 0.05）.ORR,1-year PFS,1-year OS funnel,the studies were roughly symmetricallydistributed,and there was no publication bias.One study in the 1-year PFS funnel fell outside the 95% confidence interval,suggesting heterogeneity.Sensitivity analysis was carried out for 1-year PFS.After excluding pohao Feng and other studies,the heterogeneity was significantly reduced,and then subgroup analysis was carried out according to the sample size.The heterogeneity of PFS was significantly improved 1-year after subgroup analysis.The main adverse reactions during the medication were leucopenia,thrombocytopenia,anemia,gastrointestinal reactions such as nausea and vomiting,intracranial hemorrhage,hypertension,headache and dizziness.There was no significant difference in the incidence of adverse reactions between the two groups.Conclusions: According to the existing studies,bevacizumab can effectively alleviate the disease progression and improve the survival rate of patients with lung cancer brain metastasis without increasing significant adverse reactions.